跳到正文
原文
MedPage Today·· 7 天前精选AI 评分78

美国癌症协会更新前列腺癌筛查指南

Major Change to Prostate Cancer Screening Guidelines

AI 导读

美国癌症协会(ACS)发布更新后的前列腺癌筛查指南,推荐平均风险男性在50至69岁期间每2年进行PSA检测,黑人和有强家族史的男性应从45岁开始每年筛查。此前ACS建议高风险人群在40或45岁时与医生讨论利弊。

推荐理由

ACS更新了前列腺癌筛查建议,明确推荐普通风险男性定期筛查及高危人群提前筛查,反映了累积证据的变化。

正文

— ACS now recommends PSA testing every 2 years for average-risk men ages 50 to 69

November 13, 2026 • 4 min read

  • The American Cancer Society now recommends prostate cancer screening with PSA tests every 2 years for average-risk men ages 50 t0 69 years.
  • Black men and those with strong family histories should begin annual PSA screenings at age 45.
  • The new recommendations reflect recent evidence showing that screening with PSA tests reduces the risk of dying of prostate cancer and the risk of late-stage diagnosis.

Shifting gears on prostate cancer screening, the American Cancer Society (ACS) now recommends screening with prostate-specific antigen (PSA) every 2 years for average-risk men ages 50 to 69.

Since the release of its previous guideline 16 years ago, the ACS had recommended that average-risk men consult with a physician before deciding for themselves whether to undergo a screening PSA test.

The new ACS recommendations also strengthened guidelines for men at high risk for prostate cancer, recommending annual screening beginning at age 45 for Black men and those with a strong family history of the disease. The organization previously recommended that those men discuss the pros and cons of screening with a physician at age 40 or 45.

The changes reflect the accumulation of stronger evidence that screening PSA tests reduce prostate cancer mortality and diagnosis of late-stage disease, according to the updated guidelines from Robert Smith, PhD, ACS senior vice president for early cancer detection science, and colleagues, appearing in CA: A Cancer Journal for Clinicians.

"We've just reached a point in our understanding of prostate cancer, especially that [screening] can reduce the risk of being diagnosed with metastatic disease and dying of prostate cancer," Smith told MedPage Today. "We have good protocols for avoiding harms."

Smith noted that the U.S. Preventive Services Task Force (USPSTF) has not updated their prostate cancer screening guidelines since 2018. For average-risk men, the USPSTF recommends discussion-backed decisions on PSA testing for men ages 55 to 69.

"I cannot tell you what [their recommendations] would be if they updated them today, but they did not have the data in 2018 that we had in 2025 with the update of the European trial data showing the endurance of the mortality reduction," said Smith.

The update aligns with recent evidence supporting PSA screening for prostate cancer as "one of the most important steps men can take to protect their health," said Ash Tewari, MD, of the Icahn School of Medicine at Mount Sinai in New York City.

"We have strong evidence that PSA testing can reduce the risk of dying from prostate cancer, and advances in MRI and other diagnostic tools are helping us identify potentially dangerous cancers while avoiding unnecessary procedures," he said. "Knowing your risk, getting screened regularly, and having these conversations early can save lives."

With the update, the ACS takes a clear position on prostate cancer screening, said Mark Ashamalla, MD, of Episcopal Health Services in New York City.

"For years, the ACS largely focused on encouraging men to discuss the pros and cons of PSA screening with their doctors," said Ashamalla. "Now they're taking a much clearer position and actually recommending regular screening. For men at average risk, that means a PSA blood test every 2 years between ages 50 and 69, while Black men and those with a strong family history should begin annual screening at age 45. This is a significant shift and reflects growing evidence that regular screening can reduce the risk of advanced prostate cancer and save lives."

"The goal isn't to find and treat every prostate cancer," he added. "It's to catch the dangerous ones early enough to make a difference. I think that's the biggest takeaway from these new guidelines."

By way of the guidelines, the ACS also recommends:

  • Screening every 2 years from ages 45 to 69 for non-Black men who have a first-degree relative with a prostate cancer diagnosis at age 65 or older
  • Individualized decision-making about continued screening for men 70 to 74 years, who have an uncertain balance of risks and benefits
  • Repeat PSA testing within 2 weeks to 3 months for men who have elevated PSA levels (≥3.0 ng/mL for men 45 to 69 and ≥6.5 ng/mL for men 70 to 74)
  • Clinicians should offer MRI and/or validated biomarker testing to guide biopsy decisions in men with confirmed elevated PSA levels
  • Screening is not recommended for men 75 and up, but some men ages 75 to 79 who are healthy and want to continue screening, especially with rising PSA, should discuss screening with a clinician
  • Men 80 and up should not be screened, as well as men who have a life expectancy less than 10 years

The updated guidelines are supportive of the recent trend toward active surveillance as the primary option for men with low-risk prostate cancer.

"It's important to recognize that prostate cancer screening has evolved over the past 30 years," said Smith. "More and more people appreciate that very worrisome harms associated with therapy can be avoided, especially if a man is diagnosed with prostate cancer that is not aggressive. Active treatment should be avoided until such time as it appears that the disease has become aggressive. Some men may be diagnosed with a prostate cancer that's not very aggressive, and they will live with it in that state for the rest of their lives. [They can] avoid harms that are quite diminishing to quality of life."

"On the other hand, if a man's prostate cancer becomes more aggressive, and treatment is necessary, then the process of active surveillance will at least have postponed it for a number of years, allowing men to not have to live with those [treatment-related] side effects," said Smith.

来源:MedPage Today · medpagetoday.com